Tissue photosensitizer detection by low-power remittance fluorimetry.
A simple adaptation of a commercial spectrofluorimeter which allows the semiquantitative determination of photodynamic therapy photosensitizer fluorescence in accessible tissues is described. Light from a xenon lamp is directed via a monochromator onto the tissue surface by a bifurcated random fibre bundle. Tissue fluorescence is directed to the emission monochromator and photomultiplier of the fluorimeter by the second limb of the fibre bundle. Although relatively simple, this device can be used to carry out a wide range of useful measurements in clinical and experimental photodynamic therapy. The sensitivity and reproducibility of the measurements were determined using mouse tumour and muscle tissue fluorescence measured in vivo compared with photosensitizer content measured by high performance liquid chromatography. As an illustration of the potential applications of such systems, the time courses of fluorescence in the skin of patients treated with the photosensitizers Photofrin(R) and metatetra(hydroxyphenyl)chlorin (mTHPC) (temoporfin) and the photobleaching of 5-aminolaevulinic acid-derived protoporphyrin IX during treatment, are described.
Grahn
M F
MF
Academic Department of Surgery, St Bartholomew's and The Royal London Hospital College of Medicine and Dentistry, London, UK.
De Jode
M L
ML
Dilkes
M G
MG
Ansell
J K
JK
Onwu
D
D
Maudsley
J
J
Williams
N S
NS
Cancer. 1995 Jun 1;75(11):2768-78
7743484
Br J Cancer. 1994 Nov;70(5):880-5
7947093
Arch Dermatol Res. 1995;287(7):665-74
8534131
J Natl Cancer Inst. 1961 Jan;26:1-11
13762612
Int J Cancer. 1995 Oct 9;63(2):198-204
7591204
Biomed Chromatogr. 1993 May-Jun;7(3):155-7
8318833
J Photochem Photobiol B. 1995 Apr;28(1):25-32
7791003